14,600 Shares in Cabaletta Bio, Inc. (NASDAQ:CABA) Bought by Miller Financial Services LLC

Miller Financial Services LLC purchased a new stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,600 shares of the company’s stock, valued at approximately $33,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. bought a new position in Cabaletta Bio during the third quarter worth $32,000. Point72 DIFC Ltd acquired a new position in shares of Cabaletta Bio during the third quarter valued at about $33,000. Intech Investment Management LLC bought a new stake in shares of Cabaletta Bio in the third quarter valued at about $67,000. Avanza Fonder AB acquired a new stake in Cabaletta Bio during the fourth quarter worth about $40,000. Finally, GSA Capital Partners LLP acquired a new stake in Cabaletta Bio during the third quarter worth about $127,000.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CABA. William Blair reiterated an “outperform” rating on shares of Cabaletta Bio in a research report on Monday, November 18th. Wells Fargo & Company cut Cabaletta Bio from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $12.00 to $6.00 in a research report on Thursday, December 19th. TD Cowen raised shares of Cabaletta Bio to a “strong-buy” rating in a report on Friday, November 29th. Evercore ISI downgraded shares of Cabaletta Bio from an “outperform” rating to an “inline” rating and reduced their price objective for the stock from $15.00 to $6.00 in a report on Friday, December 20th. Finally, HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Cabaletta Bio in a research report on Tuesday, February 18th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $22.71.

Cabaletta Bio Stock Performance

Shares of NASDAQ:CABA opened at $1.79 on Wednesday. The business has a fifty day moving average of $2.28 and a 200-day moving average of $3.28. Cabaletta Bio, Inc. has a twelve month low of $1.59 and a twelve month high of $21.24. The firm has a market cap of $87.49 million, a PE ratio of -0.83 and a beta of 2.58.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.